Saniona AB (publ)

Saniona AB (publ) Aktien

1,89
Saniona AB (publ), a research and development company, engages in the development of drugs for diseases of the central nervous system and eating disorders in Denmark. It has a portfolio of various drug candidates in pre-clinical and clinical stages. The company's products include Tesofensine, a triple monoamine reuptake inhibitor, which is in Phase III clinical trials to treat obesity; Tesomet, a fix-dose combination of tesofensine and metoprolol that is in Phase II clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity; NS2359, a triple monoamine reuptake inhibitor that is in Phase II clinical trial for cocaine addiction; and CAD-1883 that is in Phase II clinical trial for tremor and spinocerebellar ataxia. It is also developing SAN711 for chronic itching and neuropathic pain; Boehringer Ingelheim program for schizophrenia; IK program for inflammatory bowel diseases; Nicotinic-a6 program for parkinson's diseases; Kv7 program for pain, epilepsy, and urinary incontinence; and SAN903 for autoimmune disorders. Saniona AB (publ) was founded in 2011 and is headquartered in Ballerup, Denmark. Læs mere
Kr. 203M Markedsværdi (Mcap)
Kr. 16,8M Omsætning
Bioteknologi Industri
Sverige Handles på børsen
saniona.com Hjemmeside
Sundhed Sektor